Search
News & Events
Embrace backs WA government mental health crisis supportProfessor Helen Milroy AM has praised the WA government's additional funding for infant, child and adolescent mental health.
News & Events
2024 Seeding Grant winners announcedEmbrace 2024 Seeding Grant winners (clockwise from top left): Dr Penelope Strauss, Dr Renee Teal, Dr Melissa Licari, Dr Vincent Mancini
News & Events
Planting the seeds with new project officer Thomas BettsProject Officer Thomas Betts says it's vital we nurture our young people.
News & Events
Writing our story for Wear It Purple DayEmbrace @ The Kids Research Institute Australia celebrates Wear It Purple Day with Rio Tinto
News & Events
Baby Dreaming and Infant Mental Health Awareness WeekEmbrace @ The Kids Research Institute Australia recognises Mental Health Awareness Week, running until June 18, with the theme of ‘bonding before birth’.
News & Events
Leading youth mental health researchers welcome sector fundingLeaders of Western Australia’s youth mental health research sector from Embrace at The Kids Research Institute Australia have welcomed the state government’s $420 million boost to mental health spending in its 2023-24 budget.
News & Events
Bad news days: How to limit your child’s exposure to trauma in the mediaThe world can be a scary place for children. Wars, terrorist atrocities, natural disasters, bushfires, famine and shocking crimes are all regular features in the news we consume – not to mention the almost blanket coverage of the Covid-19 pandemic.
Sign up to join the Embrace Community Group here.
Research
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AMLHematopoietic cell transplantation (HCT) is an effective treatment for pediatric patients with high-risk, refractory, or relapsed acute myeloid leukemia (AML). However, a large proportion of transplanted patients eventually die due to relapse. To improve overall survival, we propose a combined strategy based on cord blood (CB)-HCT with the application of AML-specific T cell receptor (TCR)-engineered T cell therapy derived from the same CB graft.
Research
Effect of fractional exhaled nitric oxide (FENO)-based asthma management during pregnancy versus usual care on infant development, temperament, sensory function and autism signsAsthma during pregnancy is associated with a range of adverse perinatal outcomes. It is also linked to increased rates of neurodevelopmental conditions in the offspring. We aimed to assess whether fractional exhaled nitric oxide (FENO)-based asthma management during pregnancy improves child developmental and behavioural outcomes compared to usual care. The Breathing for Life Trial was a randomised controlled trial that compared FENO-based asthma management during pregnancy to usual care.